<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455362</url>
  </required_header>
  <id_info>
    <org_study_id>022/13 V.3.2.3</org_study_id>
    <nct_id>NCT02455362</nct_id>
  </id_info>
  <brief_title>Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Multi-site, Double-blind, Parallel Arm, Block Randomised, Placebo Controlled, Factorial Phase III Study of Opioids for Chronic Refractory Breathlessness in People With Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flinders University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flinders University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breathlessness, the sensation of breathing discomfort, is a major problem in people with
      chronic obstructive pulmonary disease (COPD). Breathlessness that persists despite optimal
      management of the underlying disease(s) is said to be refractory.

      Preliminary evidence suggests that a small, regular dose of morphine helps to reduce safely
      the sensation of breathlessness. However, this research on morphine for breathlessness has
      not defined the best way to adjust the dose of the medication, or refined which people are
      most likely to have benefit, no response or side effects.

      This is a randomized, double-blind phase III trial in people with COPD and significant
      refractory breathlessness, which will explore several important questions:

        -  Are regular, low dose opioids (morphine) at four possible doses over 3 weeks more
           effective than placebo medication (containing no active ingredient) at improving
           breathlessness?

        -  Does the medication have any effect on daily activity, breathlessness, and quality of
           life?

        -  What are the common side effects of this intervention?

        -  Does the benefit from the drug outweigh the side effects it produces?

        -  Are there specific characteristics of people who are more likely to receive benefit from
           sustained release morphine?

      Participants will be allocated to receive three weeks of morphine sulfate (and laxative,
      docusate with senna), or placebo (and placebo laxative). The dose of morphine may be
      increased each week for weeks two and three. All medicines will appear the same (blinded) and
      neither the doctor nor the participant will know which medication the participant is
      receiving.

      Participants will have a medical interview, physical examination to collect some general
      health information, and baseline measurements including; daily activity, symptoms, and
      quality of life. A small amount of blood may be required to check eligibility. Further blood
      samples may be taken at week 1 and 3 to enable testing on how individuals respond to opioids,
      further consent will be obtained for these samples. Data on benefits, side effects, and
      medical care will be collected during comprehensive weekly visits. Participants will also
      fill out a simple diary twice daily for weeks one to three of the study, and for one day each
      week during an optional 3 month extension stage.

      The outcome of this study may enable better management of symptoms and activity in people
      COPD with medicines that are shown to be effective and safe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Three hundred thousand (300,000) Australians are breathless at rest or on minimal
      exertion, often for years, despite optimal treatment of the underlying cause(s). This
      includes more than 70,000 people who are too breathless to leave their homes often for long
      periods of time. Underlying causes for such severe and ongoing breathlessness include chronic
      obstructive pulmonary disease (COPD), interstitial lung disease, heart failure,
      neurodegenerative diseases such as motor neurone disease and cachexia from any cause. The
      prevalence of chronic refractory breathlessness will continue to increase as the population
      ages because the chronic progressive diseases where breathlessness is common are increasing
      in prevalence. Nearly one half of all people experience distressing breathlessness during the
      last year of life.

      The American Thoracic Society defines breathlessness as &quot;a subjective experience of breathing
      discomfort that consists of qualitatively distinct sensations that vary in intensity&quot;. The
      term 'dyspnoea' is used interchangeably with breathlessness, shortness of breath, breathing
      difficulty and laboured breathing.

      Internationally, no medication is registered for the symptomatic reduction of chronic
      refractory breathlessness despite recommendations from the American Thoracic Society, the
      American College of Physicians, the Canadian Thoracic Society and the American College of
      Chest Physicians that regular, low-dose morphine is the evidence-based pharmaceutical option.

      Aim: To enhance the evidence base for the pharmacological treatment of chronic refractory
      breathlessness using potential therapies compared to placebo.

      Primary objective: To compare the difference of the net clinical effect (benefits and side
      effects) on chronic refractory breathlessness in people with chronic obstructive pulmonary
      disease (COPD) taking once daily, sustained release morphine at two different doses when
      compared to placebo.

      Secondary objectives.

        1. Are regular, low dose oral opioids safe, including when the dose is titrated upwards, in
           a population of people with refractory breathlessness and COPD?

        2. Do people whose breathlessness is helped by regular, low dose oral morphine get
           additional benefit by further increasing the dose of morphine?

        3. Over what period of time does benefit continue to increase once a dose level with
           benefit is achieved?

        4. What percentage of people derive clinically significant benefit at each of four dosing
           levels over and above placebo?

        5. At the lower doses, is there evidence that any benefit does not last the full 24 hours?
           (end-of-dose failure)

        6. Can we predict response, benefit and side effects from baseline demographic and clinical
           data

        7. Does the treatment of breathlessness with regular, low dose morphine have any effect on
           general health status and quality of life?

        8. Determine if there is a change in activities of daily living in those treated with
           opioids when compared to placebo.

        9. Assess any effects of each treatment on anxiety and depression.

       10. Understand the longer term benefits and side effects from sustained release morphine in
           people with COPD when compared to placebo.

       11. Do participants, while still blinded, have any preference at the end of the three week
           study?

      Sub-studies

        1. Identify pharmacokinetic and pharmacodynamic parameters that may help to predict which
           individuals will achieve the greatest benefit in week one of therapy (8mg/day,
           16mg/day).

        2. Identify pharmacogenomic variations in opioid receptors and signaling that may help to
           predict clinical response (benefit, side effects or no response).

        3. Study the effect on sleep in people participating in the study

        4. Compare the within trial incremental cost and cost effectiveness of the therapy

        5. Evaluate any changes in total testosterone from baseline to the end of the three month
           extension.

      Null hypothesis: In people who have COPD with refractory breathlessness, there is no
      difference in breathlessness intensity with the addition of regular, low dose oral sustained
      release morphine when compared to placebo.

      Alternative hypothesis: The addition of regular, low dose oral sustained release morphine
      reduces the intensity of breathlessness in people with COPD and that this occurs safely.

      Study design:

      A five stage, national, multi-site, double-blind, parallel arm, block randomised, placebo
      controlled factorial (dose increment) phase III study of opioids for chronic refractory
      breathlessness in people with COPD:

      Stage 0 - baseline (2 days); Stage 1 - randomisation #1 (1 week); Stage 2 - randomisation #2
      (1 week); Stage 3 - randomisation #3 (1 week); and Stage 4 - an optional blinded extension
      arm (up to 3 months).

      Stage 0. Baseline assessment: All consenting participants will complete 2 full days of
      baseline diary (morning and evening) in order to become accustomed to completing the diary
      regularly and to provide stable baseline data regarding breathlessness, symptoms and function
      (as measured by activPALR actigraphy). At completion of the 2 days, the participant will be
      reviewed, complete the remaining baseline assessments (questionnaires, measures and baseline
      safety data), and will then be eligible to be randomised the first time.

      Time period: Two full days (4 diary entries)

      Stage 1. Randomisation #1: Randomisation to mane orally: placebo OR 8mg KapanolR OR 16mg
      KapanolR. Twice daily diary. Participants randomised to KapanolR will also receive blinded
      docusate with sennosides, while those randomised to placebo will receive identical placebo.
      This is the primary outcome (end point) of the study.

      Time period: 1 week

      Stage 2. Randomisation #2: While continuing the arm assigned in Stage 1, add a randomisation
      to mane orally: placebo OR 8mg KapanolR. Twice daily diary. Participants who were randomised
      to placebo in Stage 1 and KapanolR in Stage 2 will have blinded docusate with sennosides
      replace placebo.

      Time period: 1 week

      Stage 3. Randomisation #3: While continuing the arm assigned in Stages 1 and 2, add a third
      randomisation to mane orally: placebo OR 8mg KapanolR. Twice daily diary. activPALR
      accelerometer worn this week. Participants who were randomised to placebo in Stages 1 and 2
      and KapanolR in Stage 3 will have blinded docusate with sennosides replace placebo.

      Time period: 1 week

      Stage 4. Extension (optional for each individual participant): Continue double blind
      medications from Stages 1, 2 and 3 for up to three months. Diary one day each week. A blood
      test at the end of the three months will be taken for total testosterone levels.

      Time period: up to 3 months.

      Target population: This study is for people with optimally treated people with mild, moderate
      or severe chronic obstructive pulmonary disease (COPD).

      Primary outcome and its assessment: Change from baseline average intensity of breathlessness
      over the previous 24 hours, measured each morning on a 11 point numerical rating scale.

      Significance: The study will answer several practical questions including whether opioids
      have a net benefit in people with COPD in reducing refractory breathlessness, whether dose
      increases beyond initial response provide a greater net benefit, the pattern of symptomatic
      response in the days after successful titration, and the proportion of people who derive a
      clinically meaningful symptomatic benefit at each dose level.

      Analysis plan: All analyses will be conducted on an intention-to-treat basis. All analyses
      will be conducted with Stata version 13.1. Missing data will be imputed using multiple
      imputation with 50 resamples drawn. The primary comparisons on which the study is powered are
      at the end of week 1: placebo compared to 8mg KapanolR daily; and placebo compared to 16mg
      KapanolR daily. Change in breathlessness in the first week between these groups will be
      evaluated using a random effects mixed model.

      Sample size calculations: All calculations assume Type I (familywise error rate (FWER)) error
      rate of 5% and Type II error rate of 20% (power of 80%) respectively. In order to account for
      attrition of 20% by the end of week 1, the study will recruit 144*100/ (100-20) = 180
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    'Recruitment not possible given changes to trial criteria
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline intensity of breathlessness over the previous 24 hours</measure>
    <time_frame>Week 1</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each evening. The primary endpoint is the difference between placebo, morphine sulfate 8 mg, or 16 mg after the first treatment week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline unpleasantness of breathlessness over the previous 24 hours</measure>
    <time_frame>Week 3</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline intensity of breathlessness &quot;right now&quot;</measure>
    <time_frame>Week 3</time_frame>
    <description>Rated on a 0-10 numerical rating scale (NRS) in a diary each morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the intensity of breathlessness</measure>
    <time_frame>Week 1</time_frame>
    <description>In addition to the NRS ratings, the intensity of breathlessness is rated on a 0-10 modified Borg scale in a evening diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current medication use and compliance</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Collected in a diary in the evening, including of any rescue medication used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Collected in a diary in the evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline physical activity using an accelerometer</measure>
    <time_frame>Week 3</time_frame>
    <description>Measured during two days at baseline and during at least five days of treatment week three.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in concurrent symptoms</measure>
    <time_frame>Week 1</time_frame>
    <description>Measured using the revised Edmonton Symptoms Assessment Scale (ESAS-r).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The modified Medical Research Council (mMRC) breathlessness scale</measure>
    <time_frame>At study end for up to 15 weeks.</time_frame>
    <description>Measures the functional impact of breathlessness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline serum testosterone level</measure>
    <time_frame>At the end of the 3 month follow-up stage, after up to 15 weeks.</time_frame>
    <description>To explore whether longer term morphine treatment is associated with decreased levels of testosterone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pharmacogenomic opioid blood profile</measure>
    <time_frame>Week 1</time_frame>
    <description>From the baseline sample, the UGT2B7*2 and *28 polymorphisms, P-glycoprotein (ABCB1 5SNPs in a haplotype block), the 5-hydroxytryptamine type 3B (HTR3B) gene rs7103572, and mu opioid receptor (A118G) polymorphisms will be measured. Interleukin 1ÃŸ, TNFalpha and Il-6 will be measured at baseline and at the end of the first treatment week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic/-kinetic blood samples</measure>
    <time_frame>Week 1</time_frame>
    <description>In a subset of 55 participants, blood parameters for morphine and its metabolites will be analysed (4 blood samples over 8 hours) at steady state of the treatment at the end of the week 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline end-tidal carbon dioxide</measure>
    <time_frame>Week 3</time_frame>
    <description>Exhaled gas measured using a non-invasive capnometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pulse oximetry</measure>
    <time_frame>Week 3</time_frame>
    <description>Non-invasive measurement of the oxygen saturation, respiratory rate, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality</measure>
    <time_frame>The final night of week 3</time_frame>
    <description>Twenty (20) participants at the Sydney and Adelaide sites will be invited to undertake a simple, non-invasive home sleep study using the ResMed ApneaLink Plus device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Rated on a 4 point Likert scale in a morning diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline sleep quality and sleep-related problems</measure>
    <time_frame>Week 3</time_frame>
    <description>The questionnaires used are the Epworth Sleepiness Scale, Leeds Sleep Questionnaire, and the Karolinska Sleepiness Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline bowel function index</measure>
    <time_frame>Week 1</time_frame>
    <description>Measure of the bowel function, during treatment with placebo / morphine sulfate 8 or 16 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline breathlessness-related quality of life</measure>
    <time_frame>Week 3</time_frame>
    <description>Measured on the CRQ-SAS Dyspnoea sub-scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline health-related quality of life</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Measured using the EQ-5D questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Life-space</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Life-Space is a measure of where a person goes, the frequency of going there, and the dependency in getting there.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Australian Karnofsky Performance Status</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>A score of 0 to 100 (in increments of 10) is assigned to participants based on their ability to undertake a range of daily tasks. The score gives an indication of the participant condition in terms of physical ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Hospital Anxiety and Depression Scale</measure>
    <time_frame>Week 3</time_frame>
    <description>A 14-item questionnaire used to measure anxiety and/or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Participant-rated seven point scale of the perception of their change, specifically their improvement since the commencement of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinded patient preference to continue treatment</measure>
    <time_frame>At study end after up to 15 weeks.</time_frame>
    <description>Participants will be asked for their preference to continue at study exit ('Is this a therapy which, on balance, you would continue to take for your breathlessness?')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economy composite</measure>
    <time_frame>During the study for up to 15 weeks.</time_frame>
    <description>Data on all health care contacts including lenght of hospitalizations, emergency department visits, DRG codes, outpatient visits to general practitioner and community nurse, and date of death.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 0, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during treatment week one and two and morphine 8 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 8, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during treatment week one and morphine 8 mg per day week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (0, 8, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 8, 8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 8, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one and two and morphine 16 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 16, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one and morphine 16 mg per day week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (8, 16, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 16, 16 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day during all three treatment weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 16, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 24, 24 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine sulfate (16, 24, 32 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine sulfate</intervention_name>
    <description>Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.</description>
    <arm_group_label>Morphine sulfate (0, 0, 8 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (0, 8, 8 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (0, 8, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 8, 8 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 8, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 16, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (8, 16, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 16, 16 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 16, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 24, 24 mg)</arm_group_label>
    <arm_group_label>Morphine sulfate (16, 24, 32 mg)</arm_group_label>
    <other_name>Kapanol(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Physician diagnosed COPD confirmed by spirometry, defined as a prior
             post-bronchodilator FEV1/FVC &lt; 0.7 in accordance with the GOLD 2014 criteria

          -  On stable medications relating to the optimal treatment of COPD or its symptomatic
             management over the prior week except routine &quot;as needed&quot; medications.

          -  Breathlessness of a level two (2) or higher on the modified Medical Research Council
             (mMRC) dyspnoea scale

          -  English speaking with sufficient reading and writing ability to complete the study
             questionnaires

          -  Assessed as competent (using SLUMS score of 27 for high school, and 25 for less than
             high school)

          -  Able and willing to give written informed consent

        Exclusion Criteria:

          -  On regularly prescribed opioid medications, including codeine preparations at or above
             8mg oral morphine equivalent daily in the previous seven (7) days.

          -  History of adverse reactions to any of the study medications or constituents in the
             placebo;

          -  Australian-modified Karnofsky performance score (AKPS) less than 50 at the beginning
             of the study.

          -  Respiratory or cardiac event in the previous one week (excluding upper respiratory
             tract infections). Illness must have resolved completely prior to baseline evaluation,
             as judged by the person's treating physician.

          -  Evidence of respiratory depression with resting respiratory rate &lt;8/min.

          -  Documented central hypoventilation syndrome.

          -  Chronic alcoholism, or previous or recent history of substance misuse.

          -  Uncontrolled nausea, vomiting or evidence of a gastrointestinal tract obstruction.

          -  Renal dysfunction with creatinine clearance calculated (MDRD) less than 20 mls/minute.

          -  Evidence of severe hepatic impairment defined as transaminases or bilirubin &gt;4x normal
             (Excluding Gilbert's syndrome)

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Currow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flinders University</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Flinders University</investigator_affiliation>
    <investigator_full_name>David Currow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

